GlassScriptPhysician profile
Kristin M Bianchi
NPI 1376953380
$10,715.06
in general payments reported to CMS, 2019-2025
33 companies · $7,474 in 2025
The $7,474 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $112 · 2021: $82.47 · 2022: $502 · 2023: $1,963 · 2024: $366 · 2025: $7,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $2,998 · Food and Beverage: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $2,997.91 |
| Food and Beverage | $2,304.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,988.65 | 2025 | |
| Medical Device Business Services, INC. | $1,089.67 | 2023 | Enseal |
| Hologic Sales and Service, LLC | $350.81 | 2022-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $322.79 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $227.89 | 2022-2023 | Ova1 |
| Pfizer INC. | $201.82 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $167.24 | 2021-2025 | |
| Astellas Pharma US INC | $166.72 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $145.31 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $138.44 | 2024-2025 | Ally II Ups, Paragard T 380a |
| Biogen, INC. | $97.22 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $92.06 | 2019-2023 | |
| Dexcom, INC. | $86.46 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $75.98 | 2021-2022 | |
| Avion Pharmaceuticals | $55.50 | 2020-2023 | Balcoltra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $52.89 | 2023-2025 | Nexplanon, Jada System |
| Ethicon US, LLC | $48.18 | 2019-2023 | Enseal |
| Exact Sciences Corporation | $43.93 | 2023-2025 | Cologuard Collection Kit |
| Gynesonics, INC. | $43.71 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Novo Nordisk INC | $38.15 | 2024 | Wegovy |
| Lupin INC. | $36.69 | 2019 | |
| Daiichi Sankyo INC. | $35.75 | 2019 | |
| Merck Sharp & Dohme LLC | $34.19 | 2023 | Gardasil 9 |
| Sanofi Pasteur INC. | $33.95 | 2024-2025 | |
| Millicent US INC | $30.54 | 2024-2025 | Intrarosa |
| Medicem INC. | $19.48 | 2022 | |
| Meditrina | $19.01 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $13.20 | 2023 | Exparel |
| Sumitomo Pharma America, INC. | $12.73 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $11.90 | 2021 | |
| Mission Pharmacal Company | $11.86 | 2019 | |
| Allergan, INC. | $11.28 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Bianchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.